- In March 2025, Chinese herbal medicines manufactured by Jiangyin Tianjiang Pharmaceutical Company Ltd. became available in Kenya after obtaining certification from the national drug regulator. This development signifies the expanding global reach of TCM in combating COVID-19
- In April 2023, researchers identified key antiviral and anti-inflammatory compounds in the TCM decoction Huashi Paidu. The study, published in the Proceedings of the National Academy of Sciences, provides scientific insight into the mechanisms by which TCM formulations combat COVID-19.
- In January 2023, China's National Health Commission issued the 10th version of its COVID-19 diagnosis and treatment protocol, emphasizing the role of TCM in treating severe and critical cases. The updated guidelines reflect the integration of TCM into the national strategy against COVID-19.
- In April 2023, the traditional Chinese medicine Qingfei Paidu received market approval in Canada, marking it as the first anti-COVID TCM product approved in a developed country. This approval signifies a significant step in the global acceptance of TCM for COVID-19 treatment.
- In March 2023, Taiwan's Ministry of Health and Welfare extended the emergency use authorization (EUA) for the herbal formula Chingguan Yihau (NRICM101) until June 2024. This extension allows pharmaceutical companies additional time to complete clinical trials and obtain formal drug permits.
